Health ❯ Healthcare ❯ Patient Care

Treatment Efficacy

Progression-Free Survival Response Rates Side Effects Long-term Outcomes Clinical Outcomes Survival Rates Side Effects Management Adverse Effects Quality of Life Clinical Trials

Novartis Breaks Ground on Texas Plant to Speed Radioligand Cancer Drug Delivery

The Denton site extends a $23 billion U.S. buildout designed to place short‑lived therapies closer to patients.

FDA Panel Rejects AstraZeneca Breast Cancer Drug, Backs Prostate Therapy

Zoldonrasib Shows Promising Early Efficacy in KRAS G12D Lung Cancer

First-in-Human SynKIR-110 Shows Safe Profile and Early Activity in Solid Tumors

Single CAR-T Infusion Puts Three Severe Autoimmune Diseases in Remission

Mexico Tightens Drug-Supply Oversight After Reaching 97% Availability

NEJM Publication Confirms Phase 3 Win for Brepocitinib in Dermatomyositis

Polilaminina Enters Regulated Testing as Lead Researcher Moves to Correct Preprint

FDA Approves Dupixent as First Treatment for Allergic Fungal Rhinosinusitis

NICE Endorses Dupilumab as First Targeted Biologic for Uncontrolled Eosinophilic COPD

Sanofi Pushes Amlitelimab Toward 2026 Filings After Mixed Phase 3 Readouts

Cosmo’s Clascoterone Meets Phase III Goals in Male-Pattern Baldness Trials

Takeda’s AI-Assisted Psoriasis Pill Succeeds in Phase 3, Outperforms Otezla

Lilly Files Orforglipron Obesity Pill With FDA After Trial Shows Weight-Loss Maintenance

Lilly’s Daily Obesity Pill Sustains Weight Loss After Switch From Wegovy or Zepbound

Nektar’s Alopecia Drug Misses Phase 2b Goal as Company Cites Ineligible Patients, Plans Phase 3

FDA Grants National Priority Voucher to J&J’s Tecvayli–Darzalex Combo in Multiple Myeloma

Tucatinib Added to First-Line HER2 Maintenance Prolongs Progression-Free Survival in Phase 3 Trial

Sacituzumab Govitecan Gains First-Line Ground in TNBC, Falls Short in Early HR+/HER2− Use

Roche’s Giredestrant Cuts Early Breast Cancer Recurrence 30% in Phase III Trial